MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Balance Sheets Overview

Current Ratio
1238.65%
Quick Ratio
1238.65%
Cash Ratio
113.50%
Debt to Asset Ratio
9.52%
Unit: Thousand (K) dollars
Assets Breakdown
    • Total current assets
    • Marketable securities - noncurre...
    • Net carrying value for the perio...
    • Others
Liabilities Breakdown
    • Additional paid-in-capital
    • Accumulated deficit
    • Lease liability
    • Others
Balance Sheets
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Cash and cash equivalents
11,327
94,064
13,153
20,611
Marketable securities
105,892
61,458
56,482
4,992
Prepaid expenses and other current assets
6,398
4,623
4,733
3,221
Total current assets
123,617
160,145
74,368
28,824
Marketable securities - noncurrent
52,550
10,076
20,812
-
Long-term equity investments
-
-
-
20,908
Net carrying value for the period ended june30, 2026
42,694
41,961
41,961
-
Restricted cash
1,931
1,931
1,931
1,931
Right-of-use asset, net
10,980
11,298
11,610
11,916
Property and equipment, net
201
217
252
269
Other assets
-
-
0
0
Total assets
231,973
225,628
150,934
63,848
Accounts payable
4,072
8,876
1,956
1,710
Accrued expenses
4,424
5,413
4,899
2,959
Current portion, lease liability
1,484
1,459
1,433
1,409
Deferred revenue
-
-
-
718
Total current liabilities
9,980
15,748
8,288
6,796
Lease liability
11,231
11,611
11,986
12,354
Royalty monetization liability
872
-
-
-
Total liabilities
22,083
27,359
20,274
19,150
Common stock, 0.001 par value 315,000,000 shares authorized 184,755,735 and 130,184,353 shares issued and outstanding at june30, 2026 and december31, 2025, respectively
185
167
130
71
Additional paid-in-capital
564,165
537,225
452,445
376,129
Accumulated other comprehensive loss
-750
-422
-202
-126
Accumulated deficit
-353,710
-338,701
-321,713
-331,376
Total stockholders equity
209,890
198,269
130,660
44,698
Total liabilities and stockholders equity
231,973
225,628
150,934
63,848
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Balance Sheets

Marketable securities$105,892K (966.17%↑ Y/Y)Cash and cashequivalents$11,327K (-60.14%↓ Y/Y)Prepaid expenses andother current assets$6,398K (70.98%↑ Y/Y)Total current assets$123,617K (193.70%↑ Y/Y)Marketable securities -noncurrent$52,550K Net carrying valuefor the period ended...$42,694K Right-of-use asset, net$10,980K (-10.11%↓ Y/Y)Restricted cash$1,931K (0.00%↑ Y/Y)Property and equipment,net$201K (-29.47%↓ Y/Y)Total assets$231,973K (199.60%↑ Y/Y)Total liabilities andstockholders equity$231,973K (199.60%↑ Y/Y)Total stockholdersequity$209,890K (276.22%↑ Y/Y)Total liabilities$22,083K (2.05%↑ Y/Y)Accumulated deficit-$353,710K (-10.81%↓ Y/Y)Accumulated othercomprehensive loss-$750K (-986.96%↓ Y/Y)Additionalpaid-in-capital$564,165K (50.44%↑ Y/Y)Lease liability$11,231K (-11.67%↓ Y/Y)Total currentliabilities$9,980K (11.83%↑ Y/Y)Royalty monetizationliability$872K Common stock, 0.001 parvalue 315,000,000...$185K (160.56%↑ Y/Y)Accrued expenses$4,424K (54.04%↑ Y/Y)Accounts payable$4,072K (3.09%↑ Y/Y)Current portion, leaseliability$1,484K (7.23%↑ Y/Y)

Ovid Therapeutics Inc. (OVID)

Ovid Therapeutics Inc. (OVID)